All News

liver,hepaitis,pink,gb

Hepatitis B Reactivation with Rituximab and Abatacept

d Jack Cush, MD

Hepatitis B reactivation is an uncommon complication of biologic therapy use. Now, a serologic study of  rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without hepatitis B antibody (HBsAb) positiv

Read Article
puzzle.RA_.jpg

RETRO - Taper or Not: You Decide

d Jack Cush, MD

A prospective, phase 3 trial of rheumatoid arthritis (RA) patients in sustained remission has shown more than half will flare if disease-modifying antirheumatic drugs (DMARD) therapy is tapered or discontinued and that remission is best maintained by continued DMARD therapy.

Read Article
FDA,approved,stamp,blue

FDA Approves Avacopan for ANCA-Associated Vasculitis

d Jack Cush, MD

October 8, 2021 the U.S.

Read Article
Triple DMARD Rx - MSH vs MLH (Lef). 136 active #RA pts given OL MTX/SSZ/HCQ vs MTX/HCQ/LEF. Equal efficacy (EULAR-Good) was seen at wk 12 (54% vs 59%) and wk 24 (65% vs 62%) - hence LEF substitution was noninferior. https://t.co/F5CGj0w7Bh

Links:

Dr. John Cush RheumNow ( View Tweet)

RETRO - Taper or Not: You Decide A prospective, phase 3 trial of RA patients in sustained remission has shown more than half will flare if DMARD therapy is tapered or discontinued and that remission is best maintained by continued DMARD therapy. https://t.co/KDqGrujGMT https://t.co/8HqSS74PqL

Links:

Dr. John Cush RheumNow ( View Tweet)
Anakinra appears to lower mortality risk (OR 0·32 vs historic controls) in hospitalized severe COVID-19 pneumonia (esp w/ hyperinflammation, CRP >100 mg/L). Metanalysis of nearly 2000 pts; better resp if given w/ dexamethasone (OR 0·23) https://t.co/7nFAkLgpGK

Links:

Dr. John Cush RheumNow ( View Tweet)

Diagnositic Imaging comparison in 36 acute Gout vs CPPD pts: - Better: MSK US sensitivity/specificity for gout 92%/83% & 91%/92% for CPPD - Less: DECT sensitivity/specificity for gout 63%/92% & 55%/92% for acute CPPD https://t.co/Ee2MFb8qyl

Links:

Dr. John Cush RheumNow ( View Tweet)

Low dose #methotrexate in primary cardiac prevention #CIRT. Trial had LESS decline in GFR in those with mild renal impairment than placebo. ?meaningful or a fluke. Either way MTX can be used safely in mild CRF! Just follow creatinine/GFR. #ClinicalPearl @RheumNow https://t.co/SyfsxZEeUH

Links:

Janet Pope Janetbirdope ( View Tweet)

As a loud, fast talking man that has no idea what he’s talking about, I can vouch for this. https://t.co/0pjuzHhEBK

Links:

Ethan Craig rheumecraig ( View Tweet)

The heterogeneous 🌍🌎🌏 world prevalence of systemic #lupus reflects heterogeneity in: ➡️ Ethnic mix ➡️ Genetic background ➡️ Age & sex ➡️ Year of the study ➡️ Socio-economic factors ➡️ Epidemiological methods ➡️ Environmental factors (?) Across populations https://t.co/QMJbJUf3vD
Laurent ARNAUD Lupusreference ( View Tweet)
Excited to share that the 2nd ed. Musculoskeletal Ultrasound in Rheumatology Review is the #1 new release in ultrasonography books on @amazon #ultrasound #RheumTwitter #meded #MedTwitter #POCUS #FOAMed https://t.co/b0ptm3MKid
Minna Kohler, MD, RhMSUS minnakohlermd ( View Tweet)
Upadacitinib was shown to be effective in two Phase 3 SELECT-AXIS trials. 1st trial: in bDMARD-IR AS pts the ASDAS resp was 44% vs 10% PBO at wk 14). 2nd trial: in nr-axSpA, the ASDAS response at wk 14: 42% vs 18% PBO. https://t.co/rnv9VVITeE

Links:

Dr. John Cush RheumNow ( View Tweet)

Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk

Links:

Dr. John Cush RheumNow ( View Tweet)

Check out the most recent podcast where we “Ask Cush Anything” and discuss a dozen news items from the last week. https://t.co/Xb81eWEZ1q #RheumNow

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical Associations with Myositis Antibodies Read the full post on #RheumNow https://t.co/tzPU1scc8x https://t.co/F537tPAQTU

Links:

Dr. John Cush RheumNow ( View Tweet)
WHO's Strategic Advisory Group on immunisation has advised an addition COVID vaccination in those >60 years and the immunosuppressed (due to a higher risk of breakthrough infections) https://t.co/NcGr8EMDaO

Links:

Dr. John Cush RheumNow ( View Tweet)

The CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million US adults have arthritis, 25.7 million of whom have AAAL. Read more on #RheumNow https://t.co/9RNIduVCZh https://t.co/fzxWMbcEfU

Links:

Dr. John Cush RheumNow ( View Tweet)
Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical Associations with Myositis Antibodies Read the full article on #RheumNow https://t.co/tzPU1scc8x https://t.co/xxF1gIulwY

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/0sL18UWjhO

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×